News und Analysen
3 Stocks Under $5 With Strong Analyst Upside Potential
At a time when many investors are rotating out of speculative penny stocks, others continue to embrace the risk-reward dynamic. Stocks that trade for under $5 carry a certain amount of risk. Many
The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway)
Penny stocks attract speculative investors looking for high-risk/high-reward opportunities. That means looking for companies with disruptive technologies, that are part of an emerging trend, or
China Eastern Airlines und die Shanghai Airport Authority stellen wichtige Erfolge auf dem North Bund International Aviation Forum 2025 vor
SHANGHAI, Nov. 01, 2025 (GLOBE NEWSWIRE) -- Das North Bund International Aviation Forum 2025 wurde heute in den Grand Halls in Shanghai, China, eröffnet. Die Veranstaltung wurde vom
These 3 Stocks Just Got Upgraded—and Could Keep Climbing
Investors watch Wall Street for signals about potential movement in stocks, and an upgrade from analysts is one important marker of shifting fundamentals. Analyst upgrades come in response to a
Solera und AkzoNobel schließen Partnerschaft zur Förderung datengestützter Nachhaltigkeit in der Fahrzeugreparatur
Die strategische Partnerschaft ermöglicht Karosseriewerkstätten und Versicherern, die CO₂-Emissionen pro Reparaturvorgang auf Basis prozessspezifischer Lack- und Energiedaten präzise zu berechnen
Qualitatives Update erstes Quartal 2025: Tecan meldet Geschäftsgang im Rahmen der Erwartungen und bestätigt den Ausblick für das Gesamtjahr 2025
Ad-hoc-Mitteilung gemäss Artikel 53 des Kotierungsreglements der SIX Swiss Exchange AG
Qualitatives Update erstes Quartal 2025: Tecan meldet Geschäftsgang im Rahmen der Erwartungen und bestätigt
EVP of North America's Largest Full Truckload Company EVP Sells All Insider Shares
Michael K Liu, EVP - Operations at Knight-Swift (NYSE:KNX), disposed of 1,243 directly held shares in an open-market sale on Feb. 4, 2026, fully exiting his direct equity position according to a SEC
One Fund Just Sold $23 Million of This Major Freight Stock. Here's What Investors Should Know
On February 4, Triton Wealth Management, PLLC reported selling 481,779 shares of Knight-Swift Transportation Holdings (NYSE:KNX), an estimated $22.58 million trade based on quarterly average
Celldex Therapeutics SVPs Engage In Heavy Transactions
On Dec. 4, 2025, Freddy A. Jimenez, Senior Vice President & General Counsel of Celldex Therapeutics (NASDAQ:CLDX), executed an open-market sale of 4,166 insider shares. See SEC Form 4 filing.
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
According to a November 14, 2025 SEC filing, HighVista Strategies LLC initiated a new stake in Cidara Therapeutics (NASDAQ:CDTX), acquiring 70,904 shares worth $6.79 million as of September 30
Executive Chairman Sells 35,000 Knight-Swift Transportation Shares for $1.8 Million. Is This a Cue to Something More Ominous?
Kevin P. Knight, Executive Chairman of Knight-Swift Transportation Holdings (NYSE:KNX), reported the indirect open-market sale of 35,000 shares for a transaction value of ~$1.8 million on Dec. 9
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover
California-based TCG Crossover Management fully exited its position in Cidara Therapeutics (NASDAQ:CDTX) during the third quarter, reducing its holdings by 1 million shares in a move valued at
Why Cidara Therapeutics Stock Crushed It Today
The leading pipeline drug being developed by Cidara Therapeutics (NASDAQ: CDTX) got a real boost from a regulator on Thursday, and the biotech's share price moved accordingly. Cidara's stock closed
Why Cidara Therapeutics Was Such a Healthy Stock Today
Cidara Therapeutics (NASDAQ: CDTX) had some encouraging news to deliver at the end of the trading week, and investors traded the biotech's stock up as a result. It closed Friday nearly 7% higher in
Why Scholar Rock Stock Bounced Higher on Monday
Monday was a good day to be invested in Scholar Rock (NASDAQ: SRRK) stock. The clinical-stage biotech received a nod from an analyst initiating coverage on its shares, a move that sent its price
ImmuCell Q2 Profit Jumps as Margins Rise
ImmuCell(NASDAQ:ICCC) reported results for the three-month period ended June 30, 2025, on August 14, 2025, highlighting a sharp rebound in profitability with adjusted EBITDA of $1.43 million
TuHURA R&D Jumps 75% in Q2
TuHURA Biosciences (NASDAQ:HURA), a biotechnology company focused on immuno-oncology therapies, released its second quarter results on August 14, 2025. The big headlines included the start of a
ImmuCell Posts 18% Gain in Q2
ImmuCell (NASDAQ:ICCC), a specialist in animal health products for the dairy and beef industries, issued its earnings results for the second quarter of fiscal 2025 on August 14, 2025. The company
PAVmed Revenue Jumps 513% in Q2
PAVmed (NASDAQ:PAVM), a medical technology innovator focused on minimally invasive diagnostics and digital health devices, published its earnings results on August 14, 2025. The headline news was a
Vaxart Revenue Jumps 520% in Fiscal Q2
Vaxart (OTC:VXRT), a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a
Pulse Biosciences Cash Jumps in Q2
Pulse Biosciences (NASDAQ:PLSE), a medical device innovator focused on nanosecond pulsed field ablation (nsPFA) for treating various conditions, released its second-quarter 2025 results on August
Cidara (CDTX) Q2 Cash Surges 163%
Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company focused on the development of innovative therapies for infectious diseases and oncology, released its second-quarter 2025 earnings on
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its
